Latest Docetaxel Stories
HORSHAM, Pa., May 25, 2011 /PRNewswire/ -- A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA(TM) (abiraterone acetate) plus prednisone compared to patients treated with prednisone plus placebo.
SOUTH SAN FRANCISCO, Calif., May 19, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.
SOUTH SAN FRANCISCO, Calif., May 18, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc.
THOUSAND OAKS, Calif., May 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced primary results of a pivotal Phase 3 trial ('147) demonstrating that XGEVA(TM) (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.
BOTHELL, WA and VANCOUVER, BC, May 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc.
TARRYTOWN, N.Y., May 3, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2011 and provided an update on development programs and upcoming milestones.
HORSHAM, Pa., April 28, 2011 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that the U.S.
PARIS and TARRYTOWN, N.Y., April 26, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc.
SEATTLE, WA, April 4 /PRNewswire-FirstCall/ - Oncothyreon Inc.
CALGARY, March 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
- totally perplexed and mixed up.